Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Immune protection against H5N1 influenza virus infection and transmission

Award Number: R01AI200072
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/03/2026
PERIOD OF PERFORMANCE END DATE: 08/31/2031

Group Awards By:

View Award Description

Immune protection against H5N1 influenza virus infection and transmission - PROJECT SUMMARY A global pandemic with a respiratory virus can be devastating, as evidenced by the SARS-CoV-2 pandemic five years ago. Highly pathogenic avian influenza viruses, including clade 2.3.4.4, have remained a major threat for causing the next pandemic. The risk of an H5 influenza pandemic has increased considerably because of the clade 2.3.4.4b H5N1 outbreak in the United States in poultry, dairy cows, and many other wildlife species. The development of effective vaccines that protect against H5N1 infection and reduce spread of the virus are urgently needed in the event of further virus adaptation and human transmission. Mucosal vaccines have the potential to induce local immunity at the portal of virus entry and provide superior protection against influenza and other respiratory viruses. The primary goal of this application is to develop a mucosal H5 influenza virus vaccine that confers robust protection against a high-dose H5N1 challenge and transmission in two different pre-clinical animal models. Univariate regression analysis will identify the dominant correlates of immune protection mediated by our mucosal vaccine. A second goal is to identify strategies and mechanisms to overcome immune imprinting and generate de novo antibody responses against epitopes on the HA protein of influenza virus that elicit potently neutralizing antibodies. Our interactive team has an established track record in designing viral immunogens, developing mucosal vaccines using the chimpanzee adenovirus vectored platform, performing pre-clinical studies, and evaluating imprinted antibody responses in humans and animal models after vaccination. Collectively, the studies described in this application have the potential to produce a single-dose H5 vaccine that protects against H5N1 virus in the setting of prior immunity to seasonal influenza viruses.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $765,798 )
2026	2026	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Allergy and Infectious Diseases Research	000	1	9/3/2026	NEW	$765,798
														Subtotal = $765,798

Grand Total All Awards = $765,798

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Immune protection against H5N1 influenza virus infection and transmission

Award Number: R01AI200072

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/03/2026

PERIOD OF PERFORMANCE END DATE: 08/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer